Diabetes Therapy
Findings describe new data in diabetes therapy research
Published in Obesity and Diabetes Week, February 28th, 2005
Study 1: Vildagliptin is a dipeptidyl-peptidase IV inhibitor used for the treatment of type 2 diabetes.
"Type 2 diabetes is characterized by chronic hyperglycemia due to the body's progressive inability to efficiently utilize insulin. The majority of individuals who develop this form of diabetes will eventually require drug therapy to control the disease and minimize the risk of complications. The incretin hormone glucagon-like peptide-1 (GLP-1) has a spectrum of effects that mimic the requirements of antidiabetic therapy. This serine protease is degraded...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathogenesis
Effects of diabetes on hepatic glucose metabolism regulation reviewed - Metabolic Syndrome
Hematological parameters associated with metabolic syndrome components - Metabolic Syndrome
Metabolic syndrome and robustness tradeoffs reviewed - Metabolic Syndrome
Relation between metabolic syndrome and inflammation reviewed - Obesity and Diabetes
High-fat diet mouse model used for studying type 2 diabetes - Obesity and Diabetes
Studies add new findings to obesity and diabetes body of knowledge - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
